trimetazidine has been researched along with cyclin d1 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chacko, SM; Hideg, K; Khan, M; Kuppusamy, ML; Kuppusamy, P; Mohan, IK; Rivera, BK; Sun, BC; Wisel, S | 1 |
1 other study(ies) available for trimetazidine and cyclin d1
| Article | Year |
|---|---|
Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.
Topics: Animals; Blotting, Western; Cell Hypoxia; Cell Survival; Cyclin D1; Disease Models, Animal; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Oxidative Stress; Oxygen Consumption; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Trimetazidine; Vasodilator Agents | 2009 |